Acute Myeloid Leukaemia (AML) is the most common and aggressive blood cancer in adults and is incurable in most patients. About 12-15% of AML patients have a mutation in the IDH2 gene that stops bone marrow cells from differentiating, or maturing, into blood cells that are required for life. Instead, these immature cells accumulate in the bone marrow and blood, which is a hallmark of AML.
'Family trees' of Acute Myeloid Leukaemia treated with enasidenib mapped for the first time
17 July 2018
The study led by MRC WIMM researchers as part of an international team aims to understand what happens when patients stop responding to treatment.